Sarepta Elevidys FDA Scrutiny - Search News

News

FDA, Sarepta and Elevidys

Reuters on MSN · 1d

FDA probes death of patient on Sarepta's Elevidys, partner Roche says death unrelated to therapy

The U.S. Food and Drug Administration said on Friday it was investigating the death of an eight-year-old boy who received Sarepta Therapeutics' muscular disorder gene therapy Elevidys.

Fierce Pharma · 5d

Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market

As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head, the biotech is standing firm behind its approved Duchenne muscular dystrophy (DMD) treatment. | As the controversy over the safety of Sarepta Therapeutics’ gene therapies comes to a head,

EconoTimes · 1d

FDA Probes Death of 8-Year-Old Linked to Sarepta’s Elevidys Gene Therapy

The U.S. Food and Drug Administration (FDA) is investigating the death of an eight-year-old boy who received Sarepta Therapeutics (NASDAQ: SRPT) gene therapy, Elevidys, for Duchenne muscular dystrophy (DMD).

GEN - Genetic Engineering and Biotechnology News1d

Sarepta Under Scrutiny, AstraZeneca’s Big Bet, and AI vs. IDRs

This week's episode covers news about Sarepta, babies born following mitochondrial transfer, and AI identifying therapy targets.

Zacks.com on MSN4d

SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny

Sarepta stock down as it halts U.S. Elevidys shipments after FDA pressure and safety concerns tied to patient deaths due to liver failure.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results